p53 overexpression in morphologically ambiguous endometrial carcinomas correlates with adverse clinical outcomes
Karuna Garg(Cleveland Clinic), Robert A. Soslow(Cleveland Clinic), Mario M. Leitão(Memorial Sloan Kettering Cancer Center), Gabriel Sica(Emory University), Christine A. Wynveen(Memorial Sloan Kettering Cancer Center), Jinru Shia(Memorial Sloan Kettering Cancer Center), Weiji Shi(Memorial Sloan Kettering Cancer Center)
Cited by 94
Related Papers
Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry
|Journal of Clinical Oncology|2005|1.1k
B7-H3: A costimulatory molecule for T cell activation and IFN-γ production
|Nature Immunology|2001|1k
Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients
|Proceedings of the National Academy of Sciences|2017|899
Type I and II Endometrial Cancers: Have They Different Risk Factors?
|Journal of Clinical Oncology|2013|833